<p>Glythera a UK based Biotechnology Compamy announces the appointment of Dr. Robert Lutz as a Chief Scientific Officer (CSO).</p><p>With more than 25 years&amp;rsquo; experience, Dr Lutz was previously Vice President of  Translation Research and Development at ImmunoGen Inc., where he was responsible for all early-stage  ADC development programs and gained further experience in directing the clinical pharmacology, biomarkers,  pharmacology and toxicology departments.</p><blockquote class="style-3"><p>With more than 25 years&amp;rsquo; experience, Dr Lutz was previously Vice President of  Translation Research and Development at ImmunoGen Inc., where he was responsible for all early-stage  ADC development programs and gained further experience in directing the clinical pharmacology, biomarkers,  pharmacology and toxicology departments.</p></blockquote><p>The Company CEO Dr Dave Simpson Said,“Robert Lutz&amp;rsquo;s experience in ADC development will be a  great asset as Glythera continues to develop our pipeline of cancer treatments.</p><p>With Robert&amp;rsquo;s appointment as CSO, and the addition of Jon Roffey to our Scientific Advisory Board,  we start 2018 in a strengthened position as developers of the very best  novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat. ”</p><p>For more information: <a href="http://www.glythera.com">Click here</a></p>